reports
- Marcel Goldmann
Investment im Fokus – Energy S.p.A. - 10.05.2024
Energy S.p.A. (Energy) entwickelt und baut auf Lithium-Ionen-Batterien basierte Energiespeichersysteme (ESS), die den von der Natur aus volatilem Strom aus erneuerbaren Energien speichern und wieder frei-geben können. Der in 2013 in Rovereto (Trient) gegründete Technologiekonzern war zuletzt insbeson-dere im privaten Wohnbereich tätig (kleine ESS), hat jedoch damit begonnen verstärkt im gewerbli-chen/industriellen Markt, der durch große und besonders große ESS gekennzeichnet ist, Fuß zu fassen. ...
Subsea 7 S.A. mandatory notification of share trades
Subsea 7 S.A. mandatory notification of share trades Luxembourg – 13 May 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) announces mandatory notification of the following share transaction by a primary insider. 1Details of the person discharging managerial responsibilities/person closely associated a)NameOlivier Blaringhem2Reason for the notification a)Position/statusExecutive VP – Subsea & Conventionalb)Initial notification/ AmendmentInitial notification3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a)NameSubsea 7 S.A.b)LEI...
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Maranello (Italy), May 13 2024 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 350 million share buyback program announced on November 7, 2023, as the fourth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Fourth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) a...
Shenzhen Kingdom Sci-tech Co Ltd: 1 director
A director at Shenzhen Kingdom Sci-tech Co Ltd bought 830,000 shares at 11.390CNY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Shijiazhuang Kelin Electric Co Ltd: 2 directors
Two Directors at Shijiazhuang Kelin Electric Co Ltd bought 824,800 shares at between 27.880CNY and 28.105CNY. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...
Nest appoints Northern Trust as Fund Administrator and Custodian
LONDON--(BUSINESS WIRE)-- Northern Trust has been appointed by Nest as the new fund administrator, helping the pension scheme coordinate its investments across its diversified portfolio. Through the newly awarded contract, Northern Trust will provide key services for Nest’s investment strategy, including custody, asset allocation and rebalancing, and performance measurement. The new partnership will oversee substantial growth in Nest, with the scheme forecast to pass £100bn AUM in 2030. This contract is therefore of significant importance to the continued success of Nest. Statement from ...
Fairfax Announces Purchase of 275,000 Subordinate Voting Shares for Ca...
Fairfax Announces Purchase of 275,000 Subordinate Voting Shares for Cancellation From Chairman and CEO, Prem Watsa TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) (“Fairfax”) announces that it has repurchased 275,000 subordinate voting shares (the “Purchased Shares”) for cancellation from its Chairman and Chief Executive Officer, Prem Watsa. The Purchased Shares are being repurchased by Fairfax at price of C$1,512.89 (the “Purchase Price”), or US$1,106.48, per share at an aggregate cost of approximately US$304.3 million. The Purchased Shar...
CNMC Goldmine Holdings Limited: 1 director
A director at CNMC Goldmine Holdings Limited sold 4,600,000 shares at 0.210SGD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Soomit Datta
Liberty LA (Buy, TP: $13, +50%) Liberty LA - Confidence in FCF grows,...
Updating estimates for Q1 we feel much better about hitting expectations for the FCF turnaround. CEO Balan Nair was sounding upbeat on the earnings call about hitting the $45m of monthly EBITDA in Puerto Rico, in our view (crucial to group FCF improvement), and we look at how to bridge that outlook from the reported Q1 number. We push up 2025 Puerto Rico EBITDA.
Chocoladefabriken Lindt & Sprungli AG: 1 director
A director at Chocoladefabriken Lindt & Sprungli AG sold 526 shares at 10,685.551CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Aksa Akrilik Kimya Sanayii A S: 1 director
A director at Aksa Akrilik Kimya Sanayii A S bought 383,000 shares at 120.300TRY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure Announce Proposed Merger Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmac...
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks Alm. Brand A/S share buy-back program Transactions during 06 May 2024 – 08 May 2024On 5 December 2023, Alm. Brand A/S announced a share buy-back program of up to DKK 250 million, as described in company announcement no. 23/2023. On 8 February 2024, Alm. Brand A/S announced an increase of the existing share buy-back programme by DKK 100 million to DKK 350 million and extension of the period for the programme until and including 30 September 2024, as described in company announcement no. 09/2024. The program is carried out in accordance with ...
Spectral Medical Announces First Quarter Results and Provides Corporat...
Spectral Medical Announces First Quarter Results and Provides Corporate Update Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throu...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company develop...
Titan Medical Reports Financial Results for the First Quarter 2024
Titan Medical Reports Financial Results for the First Quarter 2024 TORONTO, Ontario, May 13, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three months ended March 31, 2024. Recent Activities: On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement (the “Definitive Agreement”) with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction (the “Transaction”). Under the terms of the Definitive Agreement, a newly incorporated and whol...
Annovis Bio Provides Corporate Updates and Announces First Quarter 202...
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improvement...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase ...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population - In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM participants...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appoint...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.